Acute Coronary Syndrome (ACS) represents a spectrum of conditions associated with acute myocardial ischemia. Despite significant strides in understanding its pathophysiology, ACS remains a leading cause of morbidity and mortality worldwide. This article aims to outline recent advancements and best practices in ACS management.
Early diagnosis of ACS is crucial for effective management. High-sensitivity cardiac troponin assays have improved diagnostic accuracy, allowing for more rapid rule-in and rule-out of ACS. Risk stratification using tools such as the GRACE score aids in determining the most appropriate treatment strategy.
Pharmacotherapy remains a cornerstone in ACS management. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard for most patients. Recent studies suggest that potent P2Y12 inhibitors, such as ticagrelor, may provide additional benefits. Novel anticoagulants, including low molecular weight heparins and direct oral anticoagulants, have shown promise in ACS treatment.
Early invasive strategy (coronary angiography with intent to perform revascularization) is recommended for high-risk patients. Percutaneous coronary intervention (PCI) remains the preferred method of revascularization. Advances in stent technology, such as bioabsorbable stents, have improved long-term outcomes.
Secondary prevention, including lifestyle modifications and management of risk factors, is essential in reducing recurrent events. Statins, ACE inhibitors, and beta-blockers have proven efficacy in secondary prevention. Cardiac rehabilitation programs have also been shown to improve outcomes.
Advancements in ACS management have significantly improved patient outcomes. Early diagnosis, risk stratification, optimal pharmacotherapy, early invasive strategies, and secondary prevention are key components in the management of ACS. Continued research and implementation of evidence-based practices will further enhance patient care in this critical area.
1.
Is Laughter Good for Blood Glucose Control?
2.
NIH research cuts leave cancer patient facing hard choice
3.
Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.
4.
Ruxolitinib Reduces Acute GVHD in Transplant Patients
5.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
1.
The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future
2.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
3.
Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons
4.
Biomarkers of Marrow Regenerative Capacity Following Repeated Hematopoietic Stress
5.
Consensus Recommendations for Healthy Hematologic Aging
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
2.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
3.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation